| Literature DB >> 10974622 |
M J Piccart1, A Di Leo, A Hamilton.
Abstract
The past few years have witnessed an exponential increase in studies trying to identify molecular markers in patients with breast tumours that might predict for the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine kinase membrane receptor of the epidermal growth factor receptor family, has been the most widely studied marker in this respect. This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10974622 DOI： 10.1016/s0959-8049(00)00162-3
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162